Michael A. Henos

Michael A. Henos discloses dealings in 4 companies, chiefly Genoptix Inc, Crescent Biopharma, Inc. and Inhibitex Inc. In total, 40 filings cover trades dated from 18 May 2006 to 22 December 2014.

The open-market side counts 2 purchases for €52k alongside 17 sales for €26.4M. The net balance comes to €26.3M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 8 share grants and 4 option exercises. So far in 2014, the count stands at 2 purchases and 4 sales.

The newest entry dates from 23 December 2014: an open-market sale of €74k, in Crescent Biopharma, Inc. The last purchase on record was published on 13 June 2014, which is 4,515 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.